<DOC>
	<DOCNO>NCT01006629</DOCNO>
	<brief_summary>100 Russian child 2 year age less high-risk population ( preterm , and/or heart lung problem ) receive palivizumab ( Synagis ) 15 mg/kg intramuscularly prophylaxis severe respiratory syncytial virus ( RSV ) infection order study safety efficacy drug Russian subject .</brief_summary>
	<brief_title>Palivizumab Prevention Severe Respiratory Syncytial Virus Infection Russian Children</brief_title>
	<detailed_description>A prospective , multicenter , open-label , non-comparative study safety efficacy palivizumab ( Synagis ) 15 mg/kg intramuscularly prophylaxis severe low respiratory tract respiratory syncytial virus infection 100 Russian child 2 year age less high-risk population ( preterm infant [ less equal 35 week gestational age ] , infant bronchopulmonary dysplasia [ BPD ] , infant hemodynamically significant congenital heart disease [ HSCHD ] ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Subjects must meet follow criterion enrol study : 1 . Infants high risk severe RSV infection define fulfil least one following : Infants bear less equal 35 week gestational age AND less equal 6 month age enrollment Infants le equal 24 month age enrollment AND diagnosis bronchopulmonary dysplasia ( define oxygen requirement correct gestational age 36 week ) require intervention/management ( i.e. , oxygen , diuretic , bronchodilator , corticosteroid , etc . ) anytime within 6 month prior enrollment Infants less equal 24 month age enrollment hemodynamically significant congenital heart disease , either cyanotic acyanotic , unoperated partially correct . Children acyanotic cardiac lesion must pulmonary hypertension ( great equal 40 mmHg measure pressure pulmonary artery [ ultrasound acceptable ] ) need daily medication manage congenital heart disease . Children follow condition eligible : hemodynamically insignificant small atrial ventricular septal defect , patent ductus arteriosis , child aortic stenosis , pulmonic stenosis , coarctation aorta alone . 2 . Informed Consent Form sign parent ( ) . Subjects meet follow criterion eligible study : 1 . Hospitalization time enrollment ( unless discharge anticipate within 14 day ) . 2 . Mechanical ventilation ( include continuous positive airway pressure [ CPAP ] ) time enrollment . 3 . Life expectancy le 6 month . 4 . Active respiratory illness , acute infection . 5 . Known renal impairment , determine investigator . 6 . Known hepatic impairment , determine investigator . 7 . History seizure ( except neonatal seizure ) . 8 . Unstable neurological disorder ( include , restrict , epilepsy decompensated hydrocephaly ) . 9 . Known immunodeficiency , determine investigator . 10 . Allergy immunoglobulin product . 11 . Prior receipt RSV vaccine prophylaxis ( e.g. , palivizumab motavizumab ) , administration product possibly contain RSVneutralizing antibody within 100 day prior enrollment ( include , restrict , follow : RSV hyperimmunoglobulin , polyclonal intravenous immunoglobulin , cytomegalovirus hyperimmunoglobulin , varicella zoster hyperimmunoglobulin ) . 12 . Participation another clinical trial within 30 day prior enrollment . 13 . Previous enrollment trial . 14 . For reason , subject consider investigator unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Efficacy palivizumab</keyword>
	<keyword>Respiratory syncytial virus ( RSV ) infection</keyword>
	<keyword>Prevention severe RSV infection</keyword>
	<keyword>Preterm infant</keyword>
	<keyword>Infants bronchopulmonary dysplasia</keyword>
	<keyword>Infants hemodynamically significant congenital heart disease</keyword>
</DOC>